Umut Meriç – General Manager, Chiesi Turkey
Two months into the role, Umut Meriç, general manager for Chiesi Turkey, discusses the affiliate’s rapid progression and his plans to ensure Turkish patients benefit from the global company’s latest…
Chiesi, founded in 1935, serves patients in 60 countries, with a total turnover of EUR 1.3 billion per year, in the areas of respiratory disease, neonatal intensive care, allergy, and cardiology. R&D efforts are currently targeting conditions such as cystic fibrosis, organ transplantation, and rare diseases, with approximately 20 percent of annual turnover invested in R&D each year. Chiesi Turkey was founded in 2007, and has grown quickly to become the 50th ranked pharmaceutical company in the market.
Contact Details
Büyükdere Cad. No: 122 Özsezen Business Centre Block C Floor: 3
Esentepe – Sisli 34394 Istanbul / Turkey
Tel: 0212 370 91 00 –
Fax: 0212 370 91 27
info.tr@chiesi.co I
Two months into the role, Umut Meriç, general manager for Chiesi Turkey, discusses the affiliate’s rapid progression and his plans to ensure Turkish patients benefit from the global company’s latest…
Turkey is quickly becoming a regional hub for pharmaceutical industry for management, clinical trials and manufacturing, explains the general manager of Chiesi Turkey. How important is it for the government…
The founder and chairman of the rapidly expanding World Medicine group of companies discusses his firm’s international expansion strategy, how he came to the decision to invest in production and…
The secretary general of the innovators’ association gives an overview of the current structural challenges facing the pharmaceutical industry in Turkey, and discusses the changes that need to be introduced…
Menarini’s Turkish subsidiary, Ibrahim Etem Menarini, has adapted to the current pharmaceutical market and is positioned to grow in several segments including their new OTC business, but is constrained by…
Dogan Taşkent, president of the Swiss Chamber of Commerce in Turkey discusses the most successful models for innovation in Turkey, the current status of start-up incubators in the country, and…
Lundbeck Turkey’s managing director discusses CNS and mental illness in Turkey, and their recent development of manufacturing operations in Turkey for their new product. Given this specialization in and deep…
Pfizer Turkey has taken a strong supporting role in Turkey’s current strategic development plan by localizing the production of their Prix Galien winning Prevnar vaccine. Country Manager Elif Aral discusses…
The chairman of the British Chamber of Commerce in Turkey, the second oldest foreign British chamber in the world, discusses their efforts to increase investment in high value added services…
Genzyme Turkey’s general manager discusses diagnosis and treatment access issues for rare diseases, the need for prioritization of patient welfare in all aspects of health policy, and the importance of…
UCB’s managing director for Turkey and the MEA region discusses UCB’s leading patient centricity, how UCB is addressing gaps in the Turkish healthcare system surrounding epileptic patients, and the company’s plan…
Fatma Taman, Chair of ISPE and General Manager of PharmaVision, discusses the importance of proper education and training within the pharmaceutical industry to ensure the sector’s sustainable growth and development.…
The president of Turkey’s oldest pharmaceutical industry association discusses the government’s reluctance to reform the pricing system, and how this is causing the absorption of the domestic Turkish pharmaceutical industry…
The secretary general of the association representing Turkish private hospitals dicusses the private sector’s role in the Turkish healthcare system, as a subset of hospitals with a particularly high standards…
See our Cookie Privacy Policy Here